Evidence map›Paper›PMID 35839811›Full record

ReviewThe Lancet. Global health2022

Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: a review and synthetic analysis.

Laia Bruni, Beatriz Serrano, Esther Roura, Laia Alemany, Melanie Cowan, Rolando Herrero, Mario Poljak, Raul Murillo, Nathalie Broutet, Leanne M Riley and 1 more

Erratum issued Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in The Lancet. Global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07259616 (Incidence of Cervical Cancer in HPV-positive Women With Low-grade Cytological Abnormalities), which is not on this map. Cited by 332 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
332citing papers in PubMed, 13 pooled it
70.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07259616 completednot on this map

Incidence of Cervical Cancer in HPV-positive Women With Low-grade Cytological Abnormalities

TypeobservationalSponsorGynaecologisch Oncologisch Centrum ZuidRan2017 to 2023Enrolled46,079ConditionsCervical Intraepithelial Neoplasia, Cervix Uteri Cancer, Human Papilloma Virus, Cervix Carcinoma
3 · Its place in the literature

Who cites it

332 citing papers in PubMed, 13 syntheses or guidelines pooled it, 484 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Prevalence of Cervical Cancer Screening in Asia: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2025
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

272 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 7 countries.

Laia BruniCancer Epidemiology Research Programme, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain. Electronic address: lbruni@iconcologia.net.
Beatriz SerranoCancer Epidemiology Research Programme, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain.
Esther RouraCancer Epidemiology Research Programme, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain.
Laia AlemanyCancer Epidemiology Research Programme, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain.
Melanie CowanSurveillance, Monitoring, and Reporting Unit, Department of Noncommunicable Diseases, WHO, Geneva, Switzerland.
Rolando HerreroAgencia Costarricense de Investigaciones Biomédicas, Fundación INCIENSA, San José, Costa Rica; Early Detection and Prevention Section, International Agency for Research on Cancer, WHO, Lyon, France.
Mario PoljakInstitute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Raul MurilloEarly Detection and Prevention Section, International Agency for Research on Cancer, WHO, Lyon, France; Centro Javeriano de Oncología, Hospital Universitario San Ignacio, Bogotá, Colombia.
Nathalie BroutetDepartment of Reproductive Health and Research, WHO, Geneva, Switzerland.
Leanne M RileySurveillance, Monitoring, and Reporting Unit, Department of Noncommunicable Diseases, WHO, Geneva, Switzerland.
Silvia de SanjoseNational Cancer Institute, Rockville, MD, USA; ISGlobal, Barcelona, Spain.
Institut Català d'Oncologia · ESBarcelona Institute for Global Health · ESCentre International de Recherche sur le Cancer · FRCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESHospital Universitario San Ignacio · COUniversity of Ljubljana · SIWorld Health Organization · CH

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundCervical cancer screening coverage is a key monitoring indicator of the WHO cervical cancer elimination plan. We present global, regional, and national cervical screening coverage estimates against the backdrop of the 70% coverage target set by WHO.

methodsIn this review and synthetic analysis, we searched scientific literature, government websites, and official documentation to identify official national recommendations and coverage data for cervical cancer screening for the 194 WHO member states and eight associated countries and territories published from database inception until Oct 30, 2020, supplemented with a formal WHO country consultation from Nov 27, 2020, to Feb 12, 2021. We extracted data on the year of introduction of recommendations, the existence of individual invitation to participate, financing of screening tests, primary screening and triage tests used, recommended ages and screening intervals, use of self-sampling, and use of screen-and-treat approaches. We also collected coverage data, either administrative or survey-based, as disaggregated as possible by age and for any available screening interval. According to data completeness and representativeness, different statistical models were developed to produce national age-specific coverages by screening interval, which were transformed into single-age datapoints. Missing data were imputed. Estimates were applied to the 2019 population and aggregated by region and income level.

findingsWe identified recommendations for cervical screening in 139 (69%) of 202 countries and territories. Cytology was the primary screening test in 109 (78%) of 139 countries. 48 (35%) of 139 countries recommended primary HPV-based screening. Visual inspection with acetic acid was the most recommended test in resource-limited settings. Estimated worldwide coverage in women aged 30-49 years in 2019 was 15% in the previous year, 28% in the previous 3 years, and 32% in the previous 5 years, and 36% ever in lifetime. An estimated 1·6 billion (67%) of 2·3 billion women aged 20-70 years, including 662 million (64%) of 1·0 billion women aged 30-49 years, had never been screened for cervical cancer. 133 million (84%) of 158 million women aged 30-49 years living in high-income countries had been screened ever in lifetime, compared with 194 million (48%) of 404 million women in upper-middle-income countries, 34 million (9%) of 397 million women in lower-middle-income countries, and 8 million (11%) of 74 million in low-income countries.

interpretationTwo in three women aged 30-49 years have never been screened for cervical cancer. Roll-out of screening is very low in low-income and middle-income countries, where the burden of disease is highest. The priority of the WHO elimination campaign should be to increase both screening coverage and treatment of detected lesions; however, expanding the efforts of surveillance systems in both coverage and quality control are major challenges to achieving the WHO elimination target.

fundingInstituto de Salud Carlos III, European Regional Development Fund, Secretariat for Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and Horizon 2020. TRANSLATIONS: For the French, Spanish translations of the abstract see Supplementary Materials section.

Indexed as

Papillomavirus InfectionsUterine Cervical NeoplasmsAge FactorsEarly Detection of CancerFemaleHumansMass Screening

Identifiers

PMID35839811
PMCPMC9296658
OpenAlexW4285082442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.